|22nd February 2021||Jason Ehrlich||1,611||Open or private sale||$125.97||$202,940.73|
|22nd February 2021||Jason Ehrlich||2,150||Open or private sale||$124.92||$268,573.92|
|22nd February 2021||Jason Ehrlich||413||Open or private sale||$129.18||$53,349.61|
|22nd February 2021||Jason Ehrlich||1,827||Open or private sale||$127.34||$232,650.36|
|22nd February 2021||Jason Ehrlich||262||Open or private sale||$122.00||$31,963.66|
|22nd February 2021||Jason Ehrlich||687||Open or private sale||$123.56||$84,888.61|
|22nd February 2021||Jason Ehrlich||6,950||Exercise of derivative||$10.29||$71,515.50|
|17th February 2021||Bros. Advisors Lp Baker||5,792,538||Open or private purchase||$16.00||$92,680,608.00|
|17th February 2021||Bros. Advisors Lp Baker||457,462||Open or private purchase||$16.00||$7,319,392.00|
|20th January 2021||Jason Ehrlich||2,061||Open or private sale||$163.10||$336,139.21|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.